COPENHAGEN, Dec. 13 () – Novo-Nordisk, a manufacturer of anti-diabetic drugs, said on Monday it would invest 17 billion Danish kroner ($ 2.58 billion) to boost production in Denmark.
Novo, the world’s largest manufacturer of anti-diabetic drugs, said the investment would include the expansion of three new manufacturing plants and one existing plant in Kalundborg, Denmark.
The facilities mainly produce active pharmaceutical ingredients (APIs), which are the main biologically active components of medicines, as well as the collection and packaging of current and future oral and injectable drugs.
According to the plan, construction will be completed in 2027 and will create about 400 new jobs on top of the 3,200 workers in Kalundborg, Novo said.
Novo has developed a new, innovative GLP-1 drug used in the treatment of diabetes and obesity, including a tablet version of the drug semaglutide taken once a day.
The investment in Kalundborg means a doubling of the total investment in its Danish plant over the last twenty years.
Novo, which has nine production sites worldwide, announced in 2016 that it would invest $ 2 billion in a manufacturing plant in Clayton, North Carolina.
$ 1 = 6,5992 Danish Crowns Jacob Gronholt-Pedersen Report; Edited by Jason Neely